Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors
| Status: | Completed |
|---|---|
| Conditions: | Cancer, Blood Cancer, Lymphoma, Hematology, Leukemia |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 11/18/2012 |
| Start Date: | May 2011 |
| End Date: | May 2014 |
| Contact: | John Koreth, MBBS, DPhil |
| Email: | John_Koreth@dfci.harvard.edu |
| Phone: | 617-632-2949 |
Bortezomib-based Graft-Versus-Host-Disease Prophylaxis After Myeloablative Allogeneic Stem Cell Transplantation for Patients Lacking HLA-matched Related Donors: A Phase 2 Study
A common problem after stem cell transplant is graft-versus-host-disease (GVHD). GVHD is a
complication of transplantation where the donor graft attacks and damages some of your
tissues. After stem cell transplant, all patients receive prophylactic medications against
GVHD.
In this research study, we are studying the safety and effectiveness of a bortezomib based
GVHD prophylaxic drug combination in participants after myeloablative allogeneic stem call
transplantation from a matched unrelated donor, mismatched related or unrelated donor.
Before your transplant you will receive conditioning therapy with fludarabine and busulfan
given 7, 6, 5, and 4 days before your transplant. On day 0, you will receive selected blood
cells taken from your sibling or unrelated donor.
You will receive 3 drugs for your GVHD prophylaxis:
Tacrolimus will be started 3 days before your transplant. It will be given intravenously and
later by mouth. You will continue to take tacrolimus for 3 to 6 months after transplant.
Methotrexate will be given intravenously 1, 3, 6 and 11 days after your transplant.
Bortezomib will be given intravenously 1, 4, and 7 days after your transplant. On days 1, 4,
7, 30 and 3, 6 and 12 months after your transplant you will have a physical exam, blood
work, and be asked to complete a questionnaire.
Inclusion Criteria:
- Histologically or cytologically confirmed advanced and/or aggressive hematologic
malignancy (including myelodysplastic syndrome) that is unlikely to be cured by
alternative therapies
- HLA-Matched unrelated donor; or 1-locus HLA-mismatched related or unrelated donor
- ECOG performance status 0-2
- Adequate organ function
- Able to understand and willing to sign a written informed consent document
- Agrees to practice adequate contraception per study requirements
Exclusion Criteria:
- Pregnant or breastfeeding
- Recipient of prior allogeneic or autologous stem cell transplantation
- Prior abdominal radiation therapy
- HIV-positive on combination antiretroviral therapy
- Seropositive for hepatitis B or C
- Allergies to bortezomib, boron, or mannitol
- Myocardial infarction within last 6 months, NYHA Class III or IV heart failure,
uncontrolled angina, severe uncontrolled ventricular arrhythmias
- Uncontrolled bacterial, viral or fungal infections
- Seizures or history of seizures
- History of another non-hematologic malignancy unless disease-free for at least 5
years
- Uncontrolled intercurrent illness
We found this trial at
1
site
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials
